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Background: Hemodynamic support is crucial in status 1A patients. There is paucity of literature regarding the variation in the utilization 
rates of hemodynamic support in pre-transplant population.
methods: We examined UNOS database for all patients (age ≥18 years) who received heart transplantation with status 1A between 1999 
and 2013. We analyzed the variation in utilization of hemodynamic support with inotropes, intraaortic balloon pumps (IABP), extracorporeal 
membrane oxygenation (ECMO), left ventricular assist devices (VADs) and its impact on post-transplant survival.
results: We identified 13,988 patients, mean age 50.8 years, predominantly Caucasian (70.4%) males (77.8%). 1.1% patients required 
ECMO, 11.0% IABP, 36.8% LVAD, and 46.5% inotropes. IABP use declined, 16.1% in 1999 to 8.4% in 2013, p<0.001; ECMO use 
increased from 0.5% (1999) to 1.2% (2012), p=0.029; LVAD use increased from 32.3% (2004) to 49.4% (2013), p<0.001; and inotrope use 
decreased from 66.1% (1999) to 34.8% (2013), p<0.001. 6,935 patients had post transplant survival data. Multivariate analysis revealed 
worse outcome associated with ECMO (Odds ratio [OR] 0.30, p<0.001), VADs (OR 0.87, p=0.016), and IABP (OR: 0.84, p=0.035) but not 
inotropes (OR 0.99, p=0.83).
conclusion:  Utilization rates have favored VADs, with a sharp decline in the use of IABPs, and inotropes as pretransplant hemodynamic 
support strategy. All strategies except inotropes are associated with adverse survival outcomes 
